

French network of cooperative groups in oncology (GCO) at ASCO 2023 9 oral presentations, 7 poster discussions, and 6 posters



The GCO network is a French network of ten cooperative groups conducting clinical and translational research in France and in other countries on solid and liquid tumors (lung, digestive, gynecologic, lymphoma, leukemia, myeloma, head and neck, pediatric and brain cancers...).

They are all not-for-profit organizations and have been accredited as “French cooperative intergroup of international dimension in the field of cancer” by the French National Cancer Institute (INCa).

COLORECTAL AND NON COLORECTAL CANCERS	1
GYNECOLOGIC CANCERS.....	2
LUNG CANCERS	3
PEDIATRIC CANCERS.....	3
MALIGNANT HEMOPATHIES.....	4

COLORECTAL AND NON-COLORECTAL CANCERS

FFCD : Fédération Francophone de Cancérologie Digestive *Francophone Federation of Digestive Tract Cancerology*

Poster discussion session

Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.

[Abstract](#)

Claire Gallois

GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie *Multidisciplinary Oncology Cooperative Group*

Poster session

Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study.

[Abstract](#)

Benoit Rousseau

GYNECOLOGIC CANCERS

ARCAGY - Association de Recherche sur les Cancers dont GYNécologiques GINECO - Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et du sein
Cooperative Gynecological Cancer Research Group

Clinical Science Symposium

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).

[Abstract](#)

Marie Plante

Oral abstract session

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

[Abstract](#)

Isabelle Laure Ray-Coquard

Oral abstract session

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

[Abstract](#)

Philipp Harter

Oral abstract session

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

[Abstract](#)

Kathleen N. Moore

Poster discussion session

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

[Abstract](#)

Susana N. Banerjee

Poster discussion session

Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.

[Abstract](#)

Florence Joly

Oral abstract session

Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.

[Abstract](#)

Luc Cabel

LUNG CANCERS

IFCT : Intergroupe Francophone de Cancérologie Thoracique
French Cooperative Thoracic Intergroup

Oral Abstract Session

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

[Abstract](#)

Filippo Gustavo Dall'Olio

Oral abstract session

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

[Abstract](#)

Quincy S. Chu

Poster session

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.

[Abstract](#)

Anne-Claire Toffart

Poster session

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

[Abstract](#)

Lionel Falchero

Poster session

IFCT-2105 lurbinclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).

[Abstract](#)

Nicolas Girard

PEDIATRIC CANCERS

SFCE : Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent

French Society for the Fight against Cancer and Leukemia in Children and Adolescents

Poster discussion session

Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.

[Abstract](#)

Pablo Berlanga

MALIGNANT HEMOPATHIES

FIM : French Intergroup of Myeloproliferative syndromes

Poster discussion session

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.

[Abstract](#)

Helen Ajufo

Poster discussion session

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).

[Abstract](#)

Prithviraj Bose

Poster discussion session

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.

[Abstract](#)

Aaron Thomas Gerds

GRAALL: Group for Research on Adult Acute Lymphoblastic Leukemia.

Poster session

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

[Abstract](#)

Bijal D. Shah

Oral abstract session

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.

[Abstract](#)

Anthony Selwyn Stein

IFM : Intergroupe francophone du myelome

Poster session

Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).

[Abstract](#)

Cyrille Touzeau

LYSA : The LYmphoma Study Association

Oral abstract session

Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study

[Abstract](#)

Clémentine Sarkozy

- More information on the GCO network : www.gco-cancer.org

